New findings underscore Cefiderocol’s efficacy and reliability in managing complex, multidrug-resistant bacterial infections. Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) presents new data at IDWeek 2025, demonstrating broad activity of Fetroja®/Fetcroja®…
Replimune Soars Upon FDA Resubmission for Advanced Melanoma Drug Last month, investors’ hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future. Now, the regulator has accepted a refiled application after all.…
The FDA approval marks Gazyva’s first non-oncology indication, expanding Roche’s presence into autoimmune disease treatment. The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting…
Despite major therapeutic advances, patients with multiple myeloma continue to face relapse and resistance—demanding renewed focus and innovation. Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but the fight against the disease must continue. Nothing is more…
The investigational B7-H4–targeted antibody–drug conjugate HS-20089 demonstrates encouraging efficacy and manageable safety in patients with platinum-resistant ovarian cancer. Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announced positive phase 2 study findings of HS-20089, a B7-H4-targeted Antibody-drug Conjugate, in patients…
The World Health Organization confirms Fiji has eliminated trachoma as a public health problem, marking a major step toward global eye health goals. In a landmark public health achievement, Fiji has been validated by the World Health Organization (WHO) for…
Novartis Kisqali® Shows Sustained Five-Year Benefit in Broad Early Breast Cancer Population Novartis today released results from the five-year analysis of the pivotal Phase III NATALEE trial, confirming the long-term efficacy of Kisqali® (ribociclib) in patients with high-risk stage II…
CHMP Recommends Scemblix for Newly Diagnosed CML in Europe, Offering Superior Efficacy and Tolerability Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the…
Agenus Reports Durable Two-Year Survival with BOT/BAL Combination Across Refractory Solid Tumors at ESMO 2025 Agenus Inc. (Nasdaq: AGEN), a biotechnology company recognized for its pioneering work in immuno-oncology, unveiled highly encouraging new clinical data from its novel combination therapy…
Roche Unveils Promising Phase III Data for Vamikibart in Uveitic Macular Edema (UME), Highlighting Potential as First-in-Class Non-Steroidal Treatment Option Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced pivotal Phase III results from two large-scale clinical studies — MEERKAT and…
Roquette Opens State-of-the-Art Pharmaceutical Innovation Center in São Paulo to Drive Latin American Healthcare Solutions Roquette, a global leader in plant-based ingredients and pharmaceutical excipients serving the health, nutrition, and bio-industrial markets, today announced the grand opening of its dedicated…
EMD Serono Partners with U.S. Government to Expand Access to IVF Therapies for Millions of Americans EMD Serono, the healthcare division of Merck KGaA, Darmstadt, Germany, operating in the United States and Canada, has announced a groundbreaking agreement with the…